ft 25 aug 94 technolog hidden killer wait strike clive cookson continu seri drug discoveri look way fight fungal infect fungi fight side war peopl pathogen provid sever valuabl antibiot use control bacteri infect increasingli import target pharmaceut industri hospit doctor alarm rise incid life threaten fungal infect cancer transplant patient whose immun system depress chemotherapi peopl aid although reliabl estim number peopl worldwid die fungi doctor begin think hidden killer accord survey us centr diseas control rate fungal infect almost doubl 2 0 3 8 per 1 000 hospit patient 1980 1990 german studi autopsi carri frankfurt show even faster increas invas fungal infect 0 4 per cent 1978 82 1 2 per cent 1983 87 2 4 per cent 1987 92 contribut factor includ antibiot treatment wipe bacteria leav field clear compet fungi increas use hospit intraven cathet tube provid rout infect bodi well grow number immuno compromis patient meet need anti fungal drug sale expand fast datamonitor busi research compani put annual growth rate 19 per cent world market project increas dollar 2 5bn pound 1 6bn 1993 dollar 4 9bn 1997 anoth research compani frost amp sullivan estim us anti fungal market grow dollar 1 1bn 1993 dollar 2 1bn 1999 suppli side market growth driven diflucan launch pfizer us 1990 analyst expect diflucan develop pfizer uk research centr sandwich kent becom anti fungal sector first dollar 1bn year drug diflucan lead treatment system anti fungal diseas seriou infect microscop fungi spread right patient bodi amphotericin b old drug associ sever toxic side effect diflucan potenc amphotericin b fewer side effect given emerg inject treat life threaten infect taken mouth long term therapi immuno compromis patient need keep fungi bay although diflucan great improv previou treatment seriou fungal infect far perfect seriou drawback diflucan suffici broad spectrum activ work well candida yeast singl preval fungal pathogen human be much less effect aspergillu second common one omin sign diflucan resist strain candida evolv therefor pfizer develop follow drug hit fungi respond well diflucan sever compani signific presenc anti fungal market today attract potenti includ zeneca glaxo uk eli lilli merck us anti fungal drug belong class chemic call azol diflucan azol sporanox nizor daktarin three drug sold janssen belgian subsidiari johnson amp johnson number two anti fungal market behind pfizer janssen biggest develop effort moment focus extend use sporanox launch 1989 mike emanuel compani uk research director say drug great advantag broad spectrum activ includ effect aspergillu azol work block synthesi ergosterol fungal hormon essenti mainten cell membran also develop agrochem research combat fungal diseas cereal fruit sever azol develop pipelin includ one pfizer anoth zeneca phase ii clinic trial david den manchest univers medic school scientif advis fungal research trust involv clinic trial pfizer zeneca new azol could use drug think either go giant leap forward say need drug complet new mode action tall order lot fungal cell process mammalian cell den say anoth difficulti fungal cell thick coat sugar molecul find chemic structur get wall without caus damag human cell one fruit develop formul amphotericin b way reduc side effect retain potenc two us compani vestar liposom technolog encapsul amphotericin b microscop fatti particl call liposom releas drug slowli patient bodi reduc toxic product vestar ambisom liposom amphocil market zeneca outsid north american japan recent licens use sever infect respond drug best sell non azol drug lamisil launch sandoz switzerland 1991 wherea diflucan aim mainli system intern infect lamisil primari market treatment skin nail hair infect extern infect dermatophyt fungi affect 10 15 per cent popul accord david pearson sandoz although life threaten irrit disfigur extrem hard clear convent drug lamisil taken mouth appli cream effect erad dermatophyt infect also turn broader spectrum activ sandoz origin expect potenti treat system infect forecast sale dollar 800m year lamisil 1998 99 pearson say chemic lamisil allylamin interfer ergosterol product like azol earlier step biosynthet pathway effect accord sandoz lamisil fungicid actual kill wherea azol fungistat keep fungi control therefor patient treat lamisil less like relaps treatment stop principl distinct fungicid fungistat drug import say roderick hay professor cutan medicin guy hospit london practic littl clinic data yet show make differ meanwhil search continu entir new drug imperi colleg london toni barrett run particularli activ anti fungal chemistri programm promis compound investig group includ papuamin power fungicid produc natur tropic spong papulacandin hennoxazol fr 900848 research compound fujisawa japan eleg approach use fungi sourc new anti fungal drug yield sever promis research lead myco pharmaceut massachusett biotechnolog compani estim 1 5m fungal speci worldwid say william timberland myco vice presid research fungi compet natur eco system one would expect produc anti fungal protect speci seri continu next month focus drug act immun system world market major anti fungal sale dollarsm compani brand gener 1993 1997 2002 pfizer diflucan fluconazol 634 950 1 000 johnson amp johnson sporanox itraconazol 125 250 330 sandoz lamisil terbinafin 122 236 257 johnson amp johnson nizor ketoconazol 275 310 230 bayer canesten clotrimazol 150 170 182 roch loceryl amorolfin 34 84 101 bayer microspor bisonazol 76 97 100 schere plough lotrison clotrimazol 106 120 100 johnson amp johnson monistat miconazol 125 110 80 daktarin bristol myer squibb fungazon amphotericin b 60 50 40 total market 2 464 4 890 n forecast sourc datamonitor